Determining the significance of MGUS

Blood

Volumn 123, Issue 3, 2014, Pages 305-307

  Merlini, Giampaolo ^a,b  

^a Fondazione Istituto Di Ricovero E Cura A Carattere Scientifico Policlinico   (United States)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE;

AMYLOIDOSIS; ANEMIA; BONE LESION; BONE MARROW EXAMINATION; CANCER REGISTRY; CLINICAL PRACTICE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INTERVENTION STUDY; KIDNEY FAILURE; LIGHT CHAIN; MEDICAL RECORD; MONOCLONAL IMMUNOGLOBULINEMIA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SHORT SURVEY; URINARY EXCRETION; VALIDATION STUDY;

FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; LYMPHOMA; MALE; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA;

EID: 84893045216     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-12-539940     Document Type: Short Survey

References (11)

1. Turesson I, Kovalchik SA, Pfeiffer R.M., et al. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood. 2014; 123(3): 338-345.
2. Rajkumar SV, Kyle RA, Therneau T.M., et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined sign (Pubitemid 41076419)
3. Merlini G, Palladini G. Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology Am Soc Hematol Educ Program. 2012; 2012: 595-603.
4. Kyle RA, Durie BG, Rajkumar S.V., et al.; International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010; 24(6): 1121-1127.
5. Dispenzieri A, Stewart AK, Chanan-Khan A, et al. Smoldering multiple myeloma requiring treatment: time for a new definition? [Published online ahead of print October 21, 2013.] Blood. 2013.
6. Katzmann JA, Clark R, Kyle R.A., et al. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia. 2013; 27(1): 208-212.
7. Leung N, Bridoux F, Hutchison C.A., et al.; International Kidney and Monoclonal Gammopathy Research Group. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012; 120(22): 4292-4295.
8. Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013; 121(26): 5124-5130.
9. Dispenzieri A, Seenithamby K, Lacy M.Q., et al. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: A retrospective review from a tertiary referral center. Bone Marrow Transplant. 2013; 48(10): 1302-1307.
10. Therneau TM, Kyle RA, Melton LJ III, et al. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clin Proc. 2012; 87(11): 1071-1079.
11. Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013; 369(5): 438-447.